Prospective Data Collection Initiative on Thoracic Malignancies
DuTOC
2 other identifiers
observational
12,000
1 country
23
Brief Summary
Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of molecular factors, biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage. It is however still unclear which, how, and to what extent these factors will influence tumor recurrence and mortality in both early stage (I-III) and late stage (IV) thoracic malignancies such as lung cancer. Although the results from prospective clinical trials will remain the backbone of evidence-based medicine, this concerns a highly selected patient population since the large majority (85%-95%) of patients with cancer do not participate in clinical trials for various reasons. It is unlikely that trial participation will significantly improve in the near future. This fact has the following implications:
- 1.It is highly desirable to validate the results from clinical trials in the general patient population. This is complicated by the fact that the documentation of patients treated in general practice (i.e. outside the scope of clinical trials) is largely insufficient to provide comparable patient cohorts in terms of prognostic characteristics and treatment parameters.
- 2.There is an ever increasing number of therapeutic interventions available for which its efficacy depends on known and unknown tumor-specific, clinical, demographic and other patient characteristics. Large numbers of patients are required to test the relevance of these variables.
- 3.As a result of rapid technical and drug developments, new minimally invasive treatment options such as stereotactic irradiation or ablation techniques or sublobar resections and new targeted and immunotherapeutic treatments have entered the clinic. These interventions have potentially less side effects compared to the conventional treatments. Still, these new interventions will have to prove their effectiveness, safety and superiority (or non-inferiority) in a real world setting.
- 4.Many hypotheses related to further optimization of personalized medicine can currently not be tested as they require a large prospective cohort of patients, and a less time-consuming and costly research infrastructure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2025
Longer than P75 for all trials
23 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 19, 2025
CompletedFirst Posted
Study publicly available on registry
May 30, 2025
CompletedStudy Start
First participant enrolled
August 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2030
July 7, 2026
July 1, 2026
3.4 years
May 19, 2025
July 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression free survival
up to 10 years
Secondary Outcomes (5)
Disease free survival
up to 10 years
Overall survival
up to 10 years
Health related quality of life
Baseline - 3 - 6 - 12 - 24 - 36 - ... months
Health related quality of life
Baseline - 3 - 6 - 12 - 24 - 36 - ... months
Health related quality of life
Baseline - 3 - 6 - 12 - 24 - 36 - ... months
Study Arms (1)
Patients diagnosed with a thoracic malignancy
Patients diagnosed with thoracic malignancies will be asked to participate in this cohort.
Interventions
Patients who consented to the completion of questionnaires will be invited to complete questionnaires on multiple time points but not more often than once every 3 months. The length of time required for the completion of questionnaires will not exceed 150 minutes a year.
Tissue and other biomaterial, such as pleural effusion, is collected from material obtained during a diagnostic procedure or surgical resection. No additional interventional procedures are performed to obtain the material.
Blood samples can be withdrawn on multiple time points with a maximum of 10 tubes of 10 ml per year during routine blood withdrawals (or in exceptional cases with an additional blood withdrawal).
Eligibility Criteria
All patients diagnosed with a pathological confirmed thoracic malignancy, who are recently diagnosed, or have a strong suspicion without pathological confirmation but with confirmation in the multidisciplinary tumor board in one of the participating hospitals will be asked to participate in this cohort study.
You may qualify if:
- Age ≥ 18 years;
- Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board);
- Informed consent for longitudinal observational data collection;
You may not qualify if:
- Mentally challenged patients that are unable to provide conscientious informed consent as determined by the investigator.
- Inability to provide a written or electronic informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (23)
Ziekenhuis Gelderse Vallei
Ede, Gelderland, 6716 RP, Netherlands
Máxima MC
Eindhoven, North Brabant, 5504 DB, Netherlands
Tergooi MC
Hilversum, Utrecht, 1212 VG, Netherlands
Diakonessenhuis
Utrecht, Utrecht, 3582 KE, Netherlands
Noordwest Ziekenhuisgroep
Alkmaar, 1815 JD, Netherlands
Meander MC
Amersfoort, 3813TZ, Netherlands
NKI-AvL
Amsterdam, 1066 CX, Netherlands
Amphia Ziekenhuis
Breda, 4818 CK, Netherlands
Reinier de Graaf Gasthuis
Delft, 2625 AD, Netherlands
Deventer Ziekenhuis
Deventer, 7416 SE, Netherlands
Medisch Spectrum Twente
Enschede, 7512 KZ, Netherlands
Groene Hart Ziekenhuis
Gouda, 2803 HH, Netherlands
UMCG
Groningen, 9713 GZ, Netherlands
Spaarne Gasthuis
Hoofddorp, 2134 TM, Netherlands
Frisius MC
Leeuwarden, 8934 AD, Netherlands
MUMC+
Maastricht, 6229HX, Netherlands
Radboudumc
Nijmegen, 6525 GA, Netherlands
CWZ (Canisius Wilhelmina Ziekenhuis)
Nijmegen, 6532SZ, Netherlands
Erasmus MC
Rotterdam, 3015GD, Netherlands
Zuyderland
Sittard, 6162 BG, Netherlands
Haga Ziekenhuis
The Hague, 2545 AA, Netherlands
st. Antonius Ziekenhuis
Utrecht, 3543 AZ, Netherlands
UMC Utrecht
Utrecht, 3584 CX, Netherlands
Related Links
Biospecimen
Blood and tumor tissue will be stored.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
W.K. de Jong, Dr.
UMC Utrecht
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 50 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 19, 2025
First Posted
May 30, 2025
Study Start
August 15, 2025
Primary Completion (Estimated)
January 1, 2029
Study Completion (Estimated)
January 1, 2030
Last Updated
July 7, 2026
Record last verified: 2026-07